PRODUCT DATA SHEET



Bioworld Technology, Inc.

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (rHuGM-CSF)

Catalog Number: PR1035 Source: Escherichia coli. Quantity:5µg/20µg/1.0mg

Description

GM-CSF was initially characterized as a growth factor that can support the in vitro colony formation of granulocytemacrophage progenitors. It is produced by a number of different cell types (including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts) in response to cytokine or immune and inflammatory stimuli. Besides granulocyte-macrophage progenitors, GM-CSF is also a growth factor for erythroid, megakaryocyte and eosinophil progenitors. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages and eosinophils. GM-CSF has also been reported to have a functional role on non-hematopoietic cells. It can induce human endothelial cells to migrate and proliferate. Additionally, GM-CSF can also stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. GM-CSF is species specific and human GM-CSF has no biological effects on mouse cells.

Molecular Weight:

Approximately 14.6 kDa, a single non-glycosylated polypeptide chain containing 128 amino acids.

Purity:

>96% by SDS-PAGE and HPLC analyses.

Biological Activity:

Fully biologically active when compared to standard. The ED50 as calculated by the dose-dependant stimulation of the proliferation of human TF-1 cells is less then 0.1 ng/ml, corresponding to a Specific Activity of □1 x 107 IU/mg.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Lyophilized from a 0.2mm filtered concentrated solution in PBS, pH 7.4.

AA Sequence:

MAPARSPSPSTQPWEHVNAIQEARRLL N L S R D T A A E M N E T V E V I S E M F D L Q E P T CLQTRLELYKQGLRGSLTKLKGPLTMM ASHYKQHCPPTPETSCATQIITFESFKE NLKDFLLVIPFDCWEPVQE

Endotoxin:

Less than 1EU/mg of rHuGM-CSF as determined by LAL method.

Reconstitution:

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.

Storage:

This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

Usage:

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China

MADE IN CHINA

Bioworld technology, co, Ltd.

No 9, weidi road Qixia District Nanjing, 210046, P, R.China.

Email: info@biogot.com Fax:0086-025-86213570

1660 South Highway 100, Suite 500 St. Louis Park, MN 55416,USA. Email: info@bioworlde.com

Bioworld Technology, Inc.

Tel: 6123263284 Fax: 6122933841

Tel: 0086-025-86371664